Haier To Sell Pharmaceutical Stake To Sino Biopharma's Chia Tai Wing Fuk
This article was originally published in PharmAsia News
Executive Summary
Haier Group, China's largest household electrical appliances manufacturer, will transfer its holding stake in Haier Pharmaceutical to Sino Biopharmaceutical's wholly owned subsidiary Chia Tai Wing Fuk. This is the first time Haier restructured an individual business sector since beginning its diversification strategy in 1995. In 2004, Haier Pharmaceutical's sales revenue of 100 million yuan lagged far behind the 10 billion yuan of other local leading pharmaceutical firms. According to inside sources, Haier's entry in the pharmaceutical business may reap lucrative profits in the short term, but uncertainty looms for its long-term gains. Furthermore, the foray may subject the company to the risk of brand dilution and even deterioration. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.